SUMMARY
INTRODUCTION
Dysmenorrhoea is a pain occurring at or about the time of the menses. It can be classified as primary or secondary. Primary dysmenorrhoea (PD) is the occurrence of painful menstrual cramps of uterine origin which occurs in the absence of any obvious underlying disease (Akin et al, 2001; Proctor et al, 2004) . The pains are usually located in the suprapubic arearadiating to the back, sacrum or inner thighs. The pain may accompany the beginning of menstrual flow or precede it by a few hours. PD is known to manifest clinical features such as, nausea, vomiting, diarrhoea, headache and tiredness (Dawood and Ramos, 1990; Smith, 1993) .
Secondary or acquired dysmenorrhoea is pain occurring when there has been little or no pain until some disease has occurred in the pelvis. It is commonly associated with pelvis inflammation, endomentritis and fibroids (Akin et al, 2001) . Dysmenorrhoea affects 40% to 70% of women of reproductive age. It is one of the most frequent causes of absenteeism from work and school (Andersch and Milson, 1982) . The high prevalence and enormous medical, social and economic consequences of dysmenorrhoea are therefore substantial. This has led to numerous studies of its pathophysiology and treatment (Li, 1998; Zhang et al, 1998) .
While the true cause of PD remains uncertain, various hormonal activities have been implicated as causative factors. The increase in prostaglandins in the endometrium, following the fall in progesterone in the late luteal phase of the menstrual cycle which results in increased myometrial tone and excessive uterine contraction have been implicated (Akin et al, 2001) . Women with severe PD have been shown to have higher plasma concentrations of arginine vasopressin (AVP), than healthy subjects on the first day of menstruation (Stromberg et al, 1981) .
Prolactin, a stress hormone, is secreted by the anterior pituitary gland and regulated by the action of dopamine (Stromberg et al, 1981) . Prolactin has been suggested to play an essential role in the menstrual cycle as it has been linked to a number of menstrual dysfunctions (De-Cree, 1989) . Normal range of prolactin in premenopausal women is 1.2-19.5ng/ml (Ganong, 2001) . Another stress hormone is cortisol, synthesized by the adrenal cortex and regulated by adrenocorticotropic hormone (ACTH) which is an anterior pituitary hormone (Ganong, 2001) . The concentration of cortisol varies with time of day and, in women, with phase of menstruation (Kaplan et al, 1994) . According to Orth et al, (1992) and Kaplan et al, (1994) , highest concentrations range from 10-27ug/dL and are seen in the early morning, within the usual time of wakening. Plasma cortisol concentration ranges from 3-10ug/dL at 4pm and lowest levels, less than 5ug/dL are observed an hour after the usual time of sleep (Gannong, 2001) .
Different methods with varying side effects have been employed in the management of PD. In the 1960s oral contraceptives were commonly used (Menaker et al, 1962; Mathews et al, 1968) . Oral contraceptives reduce the pain of PD by reducing menstrual fluid prostaglandins, as a result of an overall decrease in menstrual fluid volume (Chan and Dawood, 1980) . The efficacy of oral contraceptives in the treatment of PD is well recognized and documented, however they have adverse effect on the gastrointestinal tract on prolong administration (Langrick et al, 1989) .
Since the 1970s, oral contraceptives have given way to non-steroidal anti-inflammatory drugs (NSAIDs) in the management of PD. However, it has been reported that only twothirds of dysmenorrhoeic women responded positively to NSAIDs, and are known to also have associated side effects (Henzl et al, 1998; Langrick et al, 1989) . Previous research studies have showed that prostaglandin was implicated in the pathogenesis of PD (Flower and Vane, 1974; Pulkkinen, 1979) ). NSAIDs act by suppressing menstrual fluid prostaglandins through enzymatic inhibition of prostaglandin.
In the 1980s a number of studies involving acupuncture on PD was carried out (Yuqin, 1994; Manheimer and Whalen, 1985; Lundeberg et al, 1985) . A preliminary trial reported that 86% of dysmenorrhoeic women treated with acupuncture had complete relief of pain for three consecutive menstrual periods (Manheimer and Whalen, 1985) . The use of acupuncture-like TENS was compared with conventional TENS and there was significant pain relief in both forms (Manheimer and Whalen, 1985) . The use of high-frequency TENS (100Hz), low frequency TENS (2Hz) and placebo-TENS was investigated in a group of dysmenorrhoeic patients. It was discovered that the patients treated with high, and low frequency TENS obtained pain relief exceeding 50% of its original intensity but in some of the low frequency subjects, the pain relief was counteracted by naxolone, a relatively pure opiate antagonist (Lundeberg et al, 1985) . A comparative study on effects of acupuncture-like TENS and placebo pill on PD revealed an average pain relief of 50% post-treatment (Lewers et al, 1989) . While different methods -with varying side effects and clinical outcome -have been employed in the management of PD, TENS has been reported to be a safe and effective nonpharmacological means of treating PD (Kaplan et al, 1994) . Also hormonal imbalance has been linked as contributing factors to the pain experienced during menstruation (Baker et al, 1999) . This study was therefore conducted to evaluate the effect of TENS on hormones (prolactin and cortisol) profile amongst University undergraduate with PD.
METHODS
Twenty one female undergraduate subjects, age 18 -26 years participated in this study. The local Ethics Committee approved the study protocol and all patients gave written informed consent. Subjects with regular menstrual periods and those without prior TENS treatment were included, while subjects on regular pain relieving drugs were excluded. Subjects were assessed by history and a detailed physical examination by a physician and a physiotherapist before inclusion in the study. 
INSTRUMENTATION

Experimental Procedure
An experimental study design made up of one group pretest and post test design was used. All the subjects completed the questionnaires and were briefed on the experimental procedure prior to the commencement of the study. On the first day of menstruation between 8.00 AM and 10.00AM, each subject indicated her pain level on the Visual Analogue Scale (VAS). Subject was then placed on supine position on a plinth, for the collection of blood sample on the median RESULTS cubital vein of the subject's arm and transferred to labeled vacutainer bottle. This serves as the pre treatment blood sample.
A total of 21 ladies of ages 18 to 26 years (mean age 23±2) with PD participated in the study. Previous methods of dysmenorrhoea pain relief used by the subjects indicate that 61.90% of the subjects commonly used analgesic drugs, 38.10% used nothing at all while none has tried the use of TENS previously. Following this procedure TENS was then administered with two pairs of electrodes placed around the painful region which is the suprapubic area in all the subjects. A pair of the adhesive electrodes was placed 10cm from the umbilicus on either side, the second pair placed on either side of the pubic symphysis close to each anterior superior iliac spine (Lundeberg et al, 1985) . High frequency TENS was applied at 100Hz and 250μs of pulse rate and pulse width respectively, the intensity was adjusted to a tolerable level of stimulation. Treatment lasted for 30 minutes. TENS application was done in supine lying position. At the termination of TENS therapy, the subjects' pain level was reassessed and a second blood sample (post treatment) obtained. All the blood samples (pre and post TENS) collected were subjected to laboratory analysis to determine the cortisol and prolactin levels in each subject using the ELISA method (Chan and Dawood, 1980) . Table 1 shows the analysis of significant difference between the pre-and posts TENS therapy Cortisol and Prolactin levels. There was a slight reduction in the mean Cortisol level from 28.45µg/dl±5.27 to 27.33µg/dl±5.13 and prolactin level from 56.81ng/ml±31.86 to 53.23ng/ml±37.63. However these differences were not statistically significant (p>0.05), using the un-paired t-test. Table 2 shows the analysis of significant difference between the pre-and post TENS application pain level on the VAS pain scale using the Wilcoxon Signed Ranks Test. There was a significant reduction (p<0.05) in the pain levels of the subjects from a value of 5.5±1.7 to 1.5±2.1 post TENS application.
Statistical Analysis DISCUSSION The demographic data of the subjects were summarized using the descriptive statistics of mean and standard deviation. Student t-test was used to determine if there was any significant difference in the pre-and post TENS prolactin and cortisol values.
It was observed in this study that there was a slight reduction in the mean values of cortisol and prolactin post-treatment, but the differences were not statistically significant (p>0.05). This agrees with the study of Rodriguez et al, (1992) who reported similar results in women with postoperative pain following hysterectomy.
Wilcoxon Signed Ranks Test was used to determine if there was any significance difference in the pain levels of the subjects preand post TENS therapy. 
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The reason for the lack of significant difference in cortisol and prolactin levels may have been attributed to the small sample size and also perhaps, if blood samples had been obtained during the TENS treatment, changes in cortisol and prolactin levels might have reveal a significant differences as suggested by the study of Kaplan et al, (1994) . Al-Damluji and Gaillard, (1987) , asserted that the novelty and unpredictability of an acute situation is an important determinant of the degree of adrenocortical responsiveness. Although the subjects in this study were aware of the experimental procedure and the discomfort of venepuncture, all the subjects had never used TENS prior to this study. Thus the experimental procedure and treatment may have represented a stressor sufficient to elicit an elevation in pretreatment cortisol and prolactin levels of subjects (Al-Damluji and Gaillard 1987; Denegar et al, 1989) . This study also showed a reduction in the mean post-treatment prolactin levels though the difference was not significant. This result supports the study of Rodriguez et al, (1992) who recorded slightly lower concentration of prolactin in response to high frequency TENS in hysterectomized women with post-operative pain.
The fact that women experienced significant reduction in pain levels is in agreement with the commonly seen trend in the literature concerning TENS as an analgesic agent in some painful conditions (Akin et al, 2001; Proctor et al, 2002) . The ability of highfrequency TENS to achieve this reduction in pain level may be explained by its effect on the Opioid-Modulating Analgesia System (OMAS). Application of TENS stimulates release of endogenous opiates (like B-endorphin) which produce analgesia (Hughes et al, 1984) . Apart from modulating pain, B-endorphin also exhibits close relationship with cortisol and prolactin (Dent et al, 1981; Plosker et al, 1990) . Bendorphin shares a common precursor with ACTH, and ACTH regulates cortisol secretion (Plosker et al, 1990) . B-endorphin also lies in close proximity to neurons which secrete dopamine into the hypothalamic -pituitary portal system. Thus, the modulation of dopamine by B-endorphin indirectly regulates prolactin secretion (Plosker et al, 1990) . The mean menstrual phase cortisol and prolactin levels in this study were above normal range for premenopausal women. This result is contrary to the study of Baker et al, (1999) , who reported that only in the luteal phase was the mean prolactin secretion for dysmenorrhoeics subjects is above the normal range.
CONCLUSION
This study concluded that high frequency TENS significantly reduced the pain levels in dysmenorrhoeic women without significantly affecting serum levels of cortisol and prolactin level.
The study also gives further evidence that women with PD have disturbed hormonal status.
